Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;41(7):623-633.
doi: 10.1002/phar.2534. Epub 2021 Jul 16.

Glucagon: Its evolving role in the management of hypoglycemia

Diana Isaacs  1 , Jennifer Clements  2 , Neil Turco  3 , Rachel Hartman  4
Affiliations
Review

Glucagon: Its evolving role in the management of hypoglycemia

Diana Isaacs et al. Pharmacotherapy. 2021 Jul.

Abstract

More than 10% of the United States population has diabetes, characterized by hyperglycemia. Insulin and other agents used to treat diabetes predispose people to hypoglycemia, which can be life threatening. Glucagon is an emergency medication that can save lives by quickly raising glucose in people who are unconscious or unable to consume glucose due to severe hypoglycemia. Although glucagon has been commercially available since 1960, earlier formulations required reconstitution of a dry powder with diluent immediately prior to injection, due to lack of long-term stability once reconstituted. Glucagon has been underutilized due to the lack of confidence or ability to administer in emergency situations. More recently, new formulations including a nasal powder glucagon and liquid-stable glucagon have become available. This article discusses the evidence surrounding new glucagon formulations compared with the original glucagon emergency kit including ease of use, efficacy, and safety with a focus on important patient counseling points and relevant clinical information on hypoglycemia.

Keywords: diabetes; glucagon; hypoglycemia.

PubMed Disclaimer

References

REFERENCES

    1. National diabetes statistics report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services. 2020. Available at: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-stat.... Accessed 17 May 2020.
    1. CDC Diabetes Atlas. Diabetes medication use. Centers for Disease Control and Prevention. Available from: gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html. Accessed 17 May 2020.
    1. Diabetes Control and Complications Trial Research Group. Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
    1. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64:631-642.
    1. Nathan DM, Cleary PA, Backlund J-YC, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.

LinkOut - more resources